Qare™ Is Here: Lōkahi Therapeutics™ Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications
Business Wire•14/10/2026•09:00 ET
0
Key Highlights
- ➤Qare launches free on App Store and Google Play, initially targeting GLP-1 medications
- ➤Qare compares self-reported results, side effects, and costs across matched user cohorts
- ➤Lōkahi expects expansion into additional therapeutic categories through organic growth and partnerships
- ➤Glucotrack operates Lōkahi Therapeutics and develops an investigational implantable continuous glucose monitor
Expert Statements
Erik Emerson, Chief Executive Officer of Lōkahi Therapeutics
“Healthcare data is a big business that many times misses in delivering actionable value for patients, providers and manufacturers. Lōkahi looks to address that”
Erik Emerson, Chief Executive Officer of Lōkahi Therapeutics
“We believe Qare™ has the potential to give patients additional context for conversations with their healthcare providers, offer providers insight into results by cohort and provide manufacturers a valuable vehicle to improve patient marketing and differentiation.”
Anna Lewandowski, Director, ai² Division
“People on GLP-1s and many other medications have tools to record their experience, but very little context for what their results mean”
Anna Lewandowski, Director, ai² Division
“Qare is designed to provide that context. As more people join, we expect each cohort to become more specific, which we believe will make the platform more useful for its users and may enable a clearer, real-world view of how users experience treatments across the industry.”
Qare™ Is Here: Lōkahi Therapeutics™ Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications
Now free on the App Store and Google Play, Qare matches users into cohorts by medication and demographic profile, generating a database of user-reported real-world experience data that Lōkahi believes may become a source of long-term value to patients and manufacturers
Get started
Create a free account to read the full story.